The loan will pay 15% interest in-kind. Representatives with Elliott, as well as Houlihan Lokey and Davis Polk & Wardwell, ...

Created by Pentagram partner Harry Pearce, the new visual identity was shaped around the concept of "one brand, one ...

Guggenheim downgraded Smartsheet (SMAR) to Neutral from Buy without a price target citing the expiration of the “go-shop” period in ...

The Museum of Modern Art in Warsaw, designed by Thomas Phifer and Partners, opened its doors this past October, showcasing works by Cecilia Vicuña, Magdalena Abakanowicz, Sandra Mujinga, Kim Gordon, ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 2.79% of ...

Fintel reports that on November 11, 2024, Guggenheim downgraded their outlook for Smartsheet (NYSE:SMAR) from Buy to Neutral.

Investors like Marc Lasry, who previously owned a stake in the Milwaukee Bucks, see sports teams as unique assets where ...

Fintel reports that on November 7, 2024, Guggenheim downgraded their outlook for Sunnova Energy International (NYSE:NOVA) ...

Leerink Partners also trimmed their target price to $45, maintaining an Outperform rating due to AnaptysBio's robust portfolio and undervalued stock. Guggenheim reiterated its Buy rating ...

Leerink Partners also trimmed their target price to $45, maintaining an Outperform rating due to AnaptysBio's robust portfolio and undervalued stock. Guggenheim reiterated its Buy rating, expressing ...

Equities researchers at StockNews.com started coverage on shares of Revance Therapeutics (NASDAQ:RVNC – Get Free Report) in a ...

Guggenheim also initiated Neutral rating. Additionally, Truist reiterated Buy rating on October 8, 2024, with a target price of $205. Seaport Research Partners analysts, in their report published on ...